Literature DB >> 15668228

Functional relevance of the conserved DNA-binding domain of STAT2.

Melissa M Brierley1, Eleanor N Fish.   

Abstract

Several distinct type I interferon (IFN)-inducible STAT2-containing complexes have been identified. For the IFN-stimulated gene factor 3 (ISGF3), STAT1 and IRF-9 mediate IFN-stimulated response element (ISRE) binding, whereas STAT2 provides a potent transactivational domain. ISGF3-independent STAT2-containing complexes, specifically STAT2:1 and STAT2:3, bind a gamma-activated sequence (GAS)-like element, yet the contribution of each STAT to DNA binding is unknown. Moreover, the contribution of these ISGF3-independent STAT2-containing complexes to IFN-inducible responses is not defined. Accordingly, we generated mutant cDNAs, targeting the DNA-binding domain in STAT2. These cDNAs were introduced by transfection into U6A cells lacking STAT2, resulting in a panel of cell lines expressing mutant STAT2 proteins. Studies assessed the sensitivity of U6A cells reconstituted with intact STAT2 (U6A-2) and cells expressing mutant STAT2s (U6A-2E426A,E427A (EE-AA), U6A-2V453I, U6A-2V454I, U6A-2V454A, U6A-2V453I,V454I(VV-II), U6A-2N458A) to IFN-inducible responses. Our data reveal that none of the mutations in the STAT2 DNA-binding domain affected IFN-inducible ISGF3 activation, and only the VV-II mutation restricted antiviral and growth inhibitory responses to IFN. Indeed, U6A-2VV-II cells are refractory to these IFN-inducible biological activities and also exhibit impaired IFN-inducible GAS-driven transcriptional activation and subsequent gene expression. Chromatin immunoprecipitation assays revealed that the VV-II mutation in STAT2 does not abrogate, but reduces the DNA binding activity of STAT2:1 heterodimers. Taken together, these data suggest a role for the conserved DNA-binding domain of STAT2 specific to the activity of ISGF3-independent STAT2-containing complexes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668228     DOI: 10.1074/jbc.M500426200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  The role of signal transducer and activator of transcription-2 in the interferon response.

Authors:  Håkan C Steen; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2012-01-26       Impact factor: 2.607

2.  Type I interferon-regulated gene expression and signaling in murine mixed glial cells lacking signal transducers and activators of transcription 1 or 2 or interferon regulatory factor 9.

Authors:  Wen Li; Markus J Hofer; Pattama Songkhunawej; So Ri Jung; Dale Hancock; Gareth Denyer; Iain L Campbell
Journal:  J Biol Chem       Date:  2017-02-17       Impact factor: 5.157

3.  Transcription factor redundancy ensures induction of the antiviral state.

Authors:  Sonja Schmid; Markus Mordstein; Georg Kochs; Adolfo García-Sastre; Benjamin R Tenoever
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

4.  Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents.

Authors:  Ziyun Du; Meiyun Fan; Jong-Gwan Kim; Dara Eckerle; Leonard Lothstein; Lai Wei; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2009-08-17       Impact factor: 5.157

5.  A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis.

Authors:  Anthony J Scarzello; Ana L Romero-Weaver; Stephen G Maher; Timothy D Veenstra; Ming Zhou; Angel Qin; Raymond P Donnelly; Faruk Sheikh; Ana M Gamero
Journal:  Mol Biol Cell       Date:  2007-04-18       Impact factor: 4.138

6.  Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.

Authors:  Yaping Sun; Y Eugene Chin; Elizabeth Weisiger; Chelsea Malter; Isao Tawara; Tomomi Toubai; Erin Gatza; Paolo Mascagni; Charles A Dinarello; Pavan Reddy
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

7.  Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

Authors:  Lisa G M van Baarsen; Saskia Vosslamber; Marianne Tijssen; Josefien M C Baggen; Laura F van der Voort; Joep Killestein; Tineke C T M van der Pouw Kraan; Chris H Polman; Cornelis L Verweij
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

Review 8.  STAT2 phosphorylation and signaling.

Authors:  Håkan C Steen; Ana M Gamero
Journal:  JAKSTAT       Date:  2013-08-12

9.  Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.

Authors:  Joshua Ogony; Hye Joung Choi; Asona Lui; Massimo Cristofanilli; Joan Lewis-Wambi
Journal:  Breast Cancer Res       Date:  2016-02-20       Impact factor: 6.466

10.  Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.

Authors:  Tamarah D de Jong; Saskia Vosslamber; Elise Mantel; Sander de Ridder; John G Wesseling; Tineke C T M van der Pouw Kraan; Cyra Leurs; Harald Hegen; Florian Deisenhammer; Joep Killestein; Ingrid E Lundberg; Jiri Vencovsky; Mike T Nurmohamed; Dirkjan van Schaardenburg; Irene E M Bultink; Alexandre E Voskuyl; D Michiel Pegtel; Conny J van der Laken; Johannes W J Bijlsma; Cornelis L Verweij
Journal:  Arthritis Res Ther       Date:  2016-02-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.